

FERMENTAS INTERNATIONAL ANNOUNCES AGREEMENT WITH SUMMIT PARTNERS

(October 9, 2007) BURLINGTON, ONTARIO; VILNIUS, LITHUANIA; AND BOSTON, MASSACHUSETTS — Fermentas International Inc., a leading developer, manufacturer and distributor of high-quality molecular biology products, today announced it has signed a definitive agreement to accept a significant minority investment from Summit Partners, a global private equity and venture capital firm that has raised nearly \$9 billion since its inception. The investment will be used to assist with Fermentas' continued rapid organic growth, as well as with new strategic partnerships and acquisitions.

Fermentas is widely regarded as a world-class provider of high-quality molecular biology products that are critical to the success of cutting edge life sciences research. Fermentas provides researchers in university and commercial laboratories with nearly 1,000 products suitable for even the most demanding applications in the genomics, proteomics, and post-genomics areas.

Fermentas' products have been produced under ISO quality and environmental management systems since 1996 (now ISO 9001 and ISO 14001). In addition, in early 2007, Fermentas completed a significant expansion of its research and manufacturing facilities in Vilnius, including a new biotechnology plant that is qualified and certified according to EU directives and ISPE guidelines for class D clean room facilities. These new facilities, together with the ISO management systems, assure customers the highest quality and reliability for all Fermentas products.

“We have developed a strong relationship with Summit Partners over the years, and they will play an important role in the ongoing growth and success of Fermentas,” said Dr. Viktoras Butkus, Chairman and Chief Executive Officer, from his office in Vilnius. “We didn't need to raise capital, but chose to do so in order to capitalize on the growth opportunities that are available to Fermentas world-wide,” added Dr. Gerhard Gerber, President.

According to Thomas Jennings, a Principal with Summit Partners who will join the Fermentas Board of Directors, “Fermentas exemplifies the type of market-leading, rapidly growing, profitable company that Summit Partners seeks for its investments. Based on Summit Partners' 23 years of investment experience in healthcare services and life sciences businesses, we believe this is an exceptional organization. We enthusiastically support Fermentas' mission and goals,” he added, “and we are committed to helping the company, its management team, and all its employees continue the tremendous success Fermentas has achieved at this point.”

About Fermentas International

The history of Fermentas dates back to 1975, when it was part of the former Institute of Applied Enzymology, a Soviet Union government funded genetic research laboratory located in Vilnius. Fermentas and its predecessors are credited with the discovery of more than 30 percent of all known restriction enzymes which are essential tools for research in molecular biology. Catalog sales of its molecular biology products were initiated in 1988, and since that time there has been robust growth in demand for Fermentas' products.

In 1995, Fermentas began operating as an independent entity, establishing joint ventures in Germany, Canada and the United States. In 2002, these were merged into Fermentas International Inc., based in Burlington, Ontario. Fermentas International (www.fermentas.com) is a leader in the discovery, manufacturing, and marketing of molecular biology products for scientific research in academic and commercial laboratories in over 70 countries around the world. A research oriented company, Fermentas delivers high-quality enzymes, markers, nucleotides, and related reagents and kits to researchers in the genomics, proteomics, and post-genomics fields.

About Summit Partners

Summit Partners (www.summitpartners.com) is a private equity and venture capital firm with offices in Boston, Palo Alto, and London. Founded in 1984, the firm has raised nearly \$9 billion in capital in its private equity, venture capital, and subordinated debt funds. Summit Partners has provided growth equity, recapitalization, and management buyout financing to more than 290 companies, which have completed nearly 125 public offerings and more than 105 strategic mergers or sales. Summit Partners seeks to work with outstanding management teams that have self-financed their companies to profitability and market leadership. Notable healthcare services and life sciences investments by Summit Partners include AmeriPath, Anesthetix Holdings, Clinical Pathology Laboratories, Clontech Laboratories, Lincare Holdings, MDVIP, NightHawk Radiology Holdings, and Pediatrix Medical Group.

The business of Summit Partners in the UK is regulated by the Financial Services Authority. Summit Partners Limited is registered in England and Wales. The registered number is 4141197, and the registered office is located at 20–22 Bedford Row in London, WC1R 4JS, UK. In the US, Summit Partners operates as an SEC-registered investment advisor. This document is intended solely to provide information regarding Summit Partners' potential financing capabilities for prospective portfolio companies.